Alvotech Expands with Acquisition of Xbrane’s R&D Operations

An announcement from Alvotech ( (ALVO) ) is now available.

On March 20, 2025, Alvotech announced the acquisition of Xbrane Biopharma AB’s R&D operations in Sweden, along with a biosimilar candidate, XB003. This strategic move is expected to enhance Alvotech’s development capabilities and establish a significant presence in the Swedish life science sector. The acquisition, valued at approximately SEK 275 million, is anticipated to close in April 2025, pending necessary approvals. This expansion supports Alvotech’s goal of increasing patient access to biologics and solidifying its position as a global leader in biosimilars development and production. The acquisition is also expected to strengthen Xbrane’s financial position, allowing it to focus on its existing portfolio and future commercialization efforts.

More about Alvotech

Alvotech is a global biotech company headquartered in Reykjavik, Iceland, specializing in the development and manufacture of biosimilar medicines. The company aims to be a leader in the biosimilar space by offering high-quality, cost-effective products and services. Alvotech has established a comprehensive network of strategic commercial partnerships to extend its reach globally, covering major markets in the United States, Europe, Asia, and other regions. Since its inception, Alvotech has invested significantly in biosimilar R&D and manufacturing, developing a robust product pipeline targeting various medical conditions.

YTD Price Performance: -13.83%

Average Trading Volume: 145,457

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $3.42B

Learn more about ALVO stock on TipRanks’ Stock Analysis page.